ANIP 41.20 ANI Pharmaceuticals Inc $ANIP Hit a 52 week high of 41.43 Closing the day 11/03/14 at 41.20 +7.24 +21.32% With a day low of 37.00 and a total volume of 1,567,962.
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ASMI: 40.99 (+8.26), SAPE: 24.60 (+7.28), PLUG: 5.14 (+0.43), ANIP: 41.20 (+7.24), ALQA: 5.24 (+0.59), YRCW: 22.29 (+0.85)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.40 (-0.30), MACK: 9.14 (-0.03), ANIP: 41.20 (+7.24), ILMN: 194.33 (+1.75)
5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 41.20 (+7.24), KTOS: 7.03 (+0.06), BLOX: 16.33 (+0.19), CSLT: 11.99 (-0.52), FPRX: 13.05 (+0.01)
ANI Pharmaceuticals Schedules Conference Call for Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 7:30AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2014 financial results on Monday, November 3, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 41.20 (+7.24)
3 Money-Making Biotech Stocks That Could Go Higher
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 24, 7:34AM CDT
Biotechnology investors often have to make bets based more on promise than profit. That's because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of...
INSY: 37.66 (-3.01), ANIP: 41.20 (+7.24), AMGN: 161.56 (-0.62), NPSP: 27.29 (-0.11), TEVA: 57.80 (+1.33)
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ADP: 81.74 (-0.04), BHP: 58.70 (-0.74), ANIP: 41.20 (+7.24), ASML: 99.55 (-0.13)
Post-Operative Pain Market 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2zmv7/postoperative) has announced the addition of the "Post-Operative Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Post-Operative Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Applied Pharma Research S.A. - Mallinckrodt Pharmaceuticals Generics - Incline Therapeutics, Inc. - Victory Pharma, Inc. - ANI Pharmaceuticals, Inc. - Baxter Healthcare Corporation - Actavis, Inc. For more information visit http://www.researchandmarkets.com/research/m2...toperative
ACT: 247.50 (+4.76), ANIP: 41.20 (+7.24), PFE: 30.19 (+0.24), PCRX: 91.26 (-1.56)
Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 41.20 (+7.24), PTN: 0.65 (+0.02), APRI: 1.53 (+0.05)
Female Sexual Dysfunction Therapeutics Pipeline Review, H2 2014 - 4 Companies & 9 Drug Profiles
M2 - Fri Sep 12, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qffhrg/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - EndoCeutics, Inc. Drug Profiles - testosterone - prasterone - bremelanotide - (bupropion hydrochloride trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor IV Agonist For more information visit http://www.researchandmarkets.com/research/qf...ale_sexual
ANIP: 41.20 (+7.24), PTN: 0.65 (+0.02)
ANI Pharmaceuticals (ANIP) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:34AM CDT
Make sure to keep a close watch on ANI Pharmaceuticals in the near future, and especially on earnings estimates following the recent slump.
ANIP: 41.20 (+7.24)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CSRE: 53.57 (-0.07), BCRH: 17.55 (-0.14), ANIP: 41.20 (+7.24), AVH: 14.54 (-0.35), EIGI: 16.69 (+0.07)
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
ABT: 43.29 (-0.30), NVO: 44.11 (-1.07), TXMD: 4.50 (+0.06), ANIP: 41.20 (+7.24), MRK: 58.92 (+0.98), AMGN: 161.56 (-0.62), TEVA: 57.80 (+1.33), NVS: 91.70 (-0.99)
ANI Pharmaceuticals (ANIP) in Focus: Stock Surges 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:44AM CDT
ANI Pharmaceuticals, Inc. (ANIP) was a big mover last session, as the company saw its shares surge 11% on the day.
MYGN: 39.48 (-0.01), ANIP: 41.20 (+7.24), ILMN: 194.33 (+1.75)
ANI Reports Second Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Aug 04, 7:30AM CDT
ANI Pharmaceuticals, Inc. ("ANI" (NASDAQ: ANIP) today reported financial results for the three and six months ended June 30, 2014 and provided revenue and adjusted non-GAAP earnings guidance for the second half of 2014.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals buys USD11m US rights to Vancocin Capsules
M2 - Mon Aug 04, 6:36AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Friday the completion of the acquisition of the US rights for Vancocin 125 mg and 250 mg capsules from Shire.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals Acquires Vancocin® Capsules and Additional Vancomycin Assets from Shire
PR Newswire - Fri Aug 01, 3:30PM CDT
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the US rights for Vancocin® 125 mg and 250 mg capsules from Shire plc, a global biopharmaceutical company. In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm ($45 million in 2013 market value, per IMS Health) and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11 million in cash for the rights to Vancocin® together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin® capsules under its own label during the fourth quarter of 2014. The transaction is immediately accretive and sales of Vancocin® capsules are expected to generate approximately $5.4 million in revenues and $4 million in non-GAAP EBITDA annually.
ANIP: 41.20 (+7.24), SHPG: 196.49 (-3.31)
ANIP Recent Posts: http://investorshangout.com/ANI-Pharmaceutica...NIP-53540/
ANIP ANI Pharmaceuticals Inc Recent Headline News
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 03, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
ASMI: 40.99 (+8.26), SAPE: 24.60 (+7.28), PLUG: 5.14 (+0.43), ANIP: 41.20 (+7.24), ALQA: 5.24 (+0.59), YRCW: 22.29 (+0.85)
ANI posts 3Q profit
Automated Insights - Mon Nov 03, 7:46AM CST
BAUDETTE, Minn. (AP) _ ANI Pharmaceuticals Inc. (ANIP) on Monday reported profit of $6.7 million in its third quarter.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals Reports Record Third Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Nov 03, 7:30AM CST
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three and nine months ended September 30, 2014 and increased its revenue and non-GAAP EBITDA guidance for the fourth quarter of 2014. ANIP: 41.20 (+7.24)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.40 (-0.30), MACK: 9.14 (-0.03), ANIP: 41.20 (+7.24), ILMN: 194.33 (+1.75)
5 Stocks Poised for Big Breakouts
at The Street - Mon Oct 27, 8:32AM CDT
These stocks look ready to break out and trade higher from current levels.
ANIP: 41.20 (+7.24), KTOS: 7.03 (+0.06), BLOX: 16.33 (+0.19), CSLT: 11.99 (-0.52), FPRX: 13.05 (+0.01)
ANI Pharmaceuticals Schedules Conference Call for Third Quarter 2014 Financial Results
PR Newswire - Mon Oct 27, 7:30AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2014 financial results on Monday, November 3, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
ANIP: 41.20 (+7.24)
3 Money-Making Biotech Stocks That Could Go Higher
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 24, 7:34AM CDT
Biotechnology investors often have to make bets based more on promise than profit. That's because it takes years and hundreds of millions of dollars to advance new medicine through clinical trials to market, so investing in biotech stocks is more of...
INSY: 37.66 (-3.01), ANIP: 41.20 (+7.24), AMGN: 161.56 (-0.62), NPSP: 27.29 (-0.11), TEVA: 57.80 (+1.33)
Zacks Rank #5 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
ADP: 81.74 (-0.04), BHP: 58.70 (-0.74), ANIP: 41.20 (+7.24), ASML: 99.55 (-0.13)
Post-Operative Pain Market 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
M2 - Thu Oct 02, 5:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m2zmv7/postoperative) has announced the addition of the "Post-Operative Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014" report to their offering. Post-Operative Pain- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. Key Topics Covered: - Indication Overview - Marketed Drugs Assessment - Marketed Details of Drugs by Application Type - Marketed Details of Drugs (NDA) by Marketing Status - Marketed Details of Drugs by Patent Expiration Timeline - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment - The API Manufacturers by the United States Drug Master File (US DMF) Status - The API Manufacturers by the US DMF Status (Drug Specific) - The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs - The API Manufacturers by the US DMF Status (Drug Specific) - Drugs Market Data and Forecasted Sales Figures (2011-2015) - Marketed Drugs Information - Drugs Description - Route of Synthesis - Global Active Pharmaceutical Manufacturers - Approval Status - Patent and Exclusivity Details - Company Overview - Phase III Drugs Information - Phase III Drugs Description - The United States Drug Master Filings (US DMF) - Discontinued Drugs Information Companies Mentioned - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Applied Pharma Research S.A. - Mallinckrodt Pharmaceuticals Generics - Incline Therapeutics, Inc. - Victory Pharma, Inc. - ANI Pharmaceuticals, Inc. - Baxter Healthcare Corporation - Actavis, Inc. For more information visit http://www.researchandmarkets.com/research/m2...toperative
ACT: 247.50 (+4.76), ANIP: 41.20 (+7.24), PFE: 30.19 (+0.24), PCRX: 91.26 (-1.56)
Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 41.20 (+7.24), PTN: 0.65 (+0.02), APRI: 1.53 (+0.05)
Female Sexual Dysfunction Therapeutics Pipeline Review, H2 2014 - 4 Companies & 9 Drug Profiles
M2 - Fri Sep 12, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qffhrg/female_sexual) has announced the addition of the "Female Sexual Dysfunction - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Sexual Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Palatin Technologies, Inc. - M et P Pharma AG - ANI Pharmaceuticals, Inc. - EndoCeutics, Inc. Drug Profiles - testosterone - prasterone - bremelanotide - (bupropion hydrochloride trazodone hydrochloride) - TBS-2 - PL-6983 - S1B-307 - S1B-3006 - Next Generation Melanocortin Receptor IV Agonist For more information visit http://www.researchandmarkets.com/research/qf...ale_sexual
ANIP: 41.20 (+7.24), PTN: 0.65 (+0.02)
ANI Pharmaceuticals (ANIP) Falls: Stock Goes Down 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 7:34AM CDT
Make sure to keep a close watch on ANI Pharmaceuticals in the near future, and especially on earnings estimates following the recent slump.
ANIP: 41.20 (+7.24)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CSRE: 53.57 (-0.07), BCRH: 17.55 (-0.14), ANIP: 41.20 (+7.24), AVH: 14.54 (-0.35), EIGI: 16.69 (+0.07)
Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk
M2 - Wed Aug 20, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6xznb6/global_hormone) has announced the addition of the "Global Hormone Replacement Therapy Market 2014-2018" report to their offering. Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer. The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018. The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Actavis plc - Bayer AG - Merck & Co. Inc. - Novartis AG - Novo Nordisk A/S - Abbott Laboratories Ltd. - Amgen Inc. - ANI Pharmaceuticals Inc. - Hisamitsu Pharmaceutical Co. Inc. - MylanLaboratories Inc. - Orion Corp. - QuatRx Pharmaceuticals Co. - Teva Pharmaceutical Industries Ltd. - TherapeuticsMD Inc. For more information visit http://www.researchandmarkets.com/research/6x...al_hormone
ABT: 43.29 (-0.30), NVO: 44.11 (-1.07), TXMD: 4.50 (+0.06), ANIP: 41.20 (+7.24), MRK: 58.92 (+0.98), AMGN: 161.56 (-0.62), TEVA: 57.80 (+1.33), NVS: 91.70 (-0.99)
ANI Pharmaceuticals (ANIP) in Focus: Stock Surges 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 05, 7:44AM CDT
ANI Pharmaceuticals, Inc. (ANIP) was a big mover last session, as the company saw its shares surge 11% on the day.
MYGN: 39.48 (-0.01), ANIP: 41.20 (+7.24), ILMN: 194.33 (+1.75)
ANI Reports Second Quarter 2014 Financial Results and Year-To-Date Highlights
PR Newswire - Mon Aug 04, 7:30AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three and six months ended June 30, 2014 and provided revenue and adjusted non-GAAP earnings guidance for the second half of 2014. ANIP: 41.20 (+7.24)
ANI Pharmaceuticals buys USD11m US rights to Vancocin Capsules
M2 - Mon Aug 04, 6:36AM CDT
Pharmaceutical company ANI Pharmaceuticals (NasdaqGM:ANIP) revealed on Friday the completion of the acquisition of the US rights for Vancocin 125 mg and 250 mg capsules from Shire.
ANIP: 41.20 (+7.24)
ANI Pharmaceuticals Acquires Vancocin® Capsules and Additional Vancomycin Assets from Shire
PR Newswire - Fri Aug 01, 3:30PM CDT
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the US rights for Vancocin® 125 mg and 250 mg capsules from Shire plc, a global biopharmaceutical company. In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm ($45 million in 2013 market value, per IMS Health) and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11 million in cash for the rights to Vancocin® together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin® capsules under its own label during the fourth quarter of 2014. The transaction is immediately accretive and sales of Vancocin® capsules are expected to generate approximately $5.4 million in revenues and $4 million in non-GAAP EBITDA annually.
ANIP: 41.20 (+7.24), SHPG: 196.49 (-3.31)
